Клиническая микробиология и антимикробная химиотерапия (Jun 2021)

Official statements of the board of experts on the use of topical thiamphenicol in patients with communityacquired respiratory infections

  • Avdeev S.N.,
  • Garashchenko T.I.,
  • Geppe N.A.,
  • Dronov I.A.,
  • zaicev_aa,
  • Ivanchik N.V.,
  • Ilenko L.I.,
  • Karpova E.P.,
  • Kozlov R.S.,
  • Kozlova L.V.,
  • Kolosova N.G.,
  • Malahov A.B.,
  • Nikiforova G.N.,
  • Odinaeva N.D.,
  • Svistushkin V.M.,
  • Edelstein M.V.

DOI
https://doi.org/10.36488/cmac.2021.2.195-196
Journal volume & issue
Vol. 23, no. 2
pp. 195 – 196

Abstract

Read online

Currently, there is a steady growth antimicrobial resistance (AMP) worldwide. This is especially true now when antibiotic use has become uncontrolled due to its use in COVID-19 treatment regimens. Antibiotics do not have antiviral effect, their appointment is justified only with complicated forms of COVID-19. Moreover, such a massive use antibiotics creates the prerequisites for the formation antibiotic resistance, including among the causative agents of community-acquired infections. Due to the relentless the growth of antibiotic resistance of community-acquired pathogens of respiratory diseases, it becomes necessary to revise approaches to antibacterial therapy (ABT) and assessing the potential use of thiamphenicol for the treatment of community-acquired infections caused by respiratory pathogens.